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Abstract 27 
Study Objective Current guidelines recommend higher daptomycin doses than the label dose 28 
of 6 mg/kg for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, the 29 
evidence supporting this is from in vitro and cases series studies. The objective of this study 30 
was to evaluate the comparative effectiveness of daptomycin dose in MRSA bacteremia.  31 
Design Retrospective national cohort study 32 
Setting Veterans Affairs Medical Centers 33 
Patients A total of 371 patients with MRSA bacteremia between 2002 and 2015 treated initially 34 
with vancomycin within 24 hours of initial culture collection and switched to daptomycin therapy 35 
within 7 days were included in the study, with 138 patients (37.2%) receiving higher than label 36 
daptomycin dose.  37 
Measurements and Main Results Clinical outcomes were compared among those with 38 
daptomycin label dose (6 mg/kg) and those with higher dose (≥7mg/kg), using propensity score 39 
matched Cox proportional hazards regression models. To identify dose partitioning associated 40 
with optimal survival, categorization and regression tree (CART) analysis was used among 41 
patients controlling for confounding with a 30-day mortality disease risk score. Propensity score 42 
matched 30-day mortality was 8.6% (6/70) among higher dose vs 18.6% (13/70) among label 43 
dose (hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.10-0.94). No differences were 44 
observed in inpatient mortality, length of stay, 30-day readmission, or 30-day S. aureus 45 
reinfection. CART analysis resulted in doses of ≥7mg/kg providing benefit only among patients 46 
with higher (>51%) predicted probabilities of 30-day mortality (p<0.001). 47 
Conclusion This is the first comparative effectiveness study of daptomycin dose in MRSA 48 
bacteremia. Survival benefits were observed with higher than label daptomycin dose (≥7mg/kg) 49 
for the treatment of MRSA bacteremia. These data suggest higher than label doses of 50 
daptomycin may be preferred over label dose for improving clinical outcomes in MRSA 51 
bacteremia.   52 
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Introduction 53 
Staphylococcus aureus bloodstream infections (BSIs) contribute to significant mortality rates, 54 
approximately 20%.1 Label dose of daptomycin for Staphylococcus aureus BSI with or without 55 
infective endocarditis was established in a randomized study at 6 mg/kg based on daptomycin’s 56 
non-inferiority to the standard of care, vancomycin, with or without an aminoglycoside.2 More 57 
recent data has suggested improved outcomes with daptomycin over vancomycin in MRSA 58 
BSI.3, 4 However, the optimal dose of daptomycin for MRSA-BSI remains unclear. 59 
 60 
Current national guidelines yield varying recommendations on daptomycin dose for MRSA-BSIs, 61 
generally recommending ≥8 mg/kg.5-8 These recommendations are based predominantly on in 62 
vitro data and a case series of 61 patients receiving a mean daptomycin dose of 8 mg/kg with 63 
any type of infection, at any site, caused by any gram-positive organism.9-13 To date, no studies 64 
have examined the comparative effectiveness of daptomycin label dose to higher dose in MRSA 65 
BSI. Therefore, the objective of this study was to evaluate clinical outcomes among higher than 66 
label daptomycin dose in MRSA BSI.  67 
 68 
Methods 69 
Study Population 70 
Our study population included patients age ≥ 18 years who were admitted to any Veterans 71 
Affairs medical center between January 1, 2002 to October 14, 2015 with MRSA bacteremia 72 
based blood cultures positive for MRSA. Patients initiated on vancomycin within 24 hours of 73 
initial culture collection and then switched to daptomycin within 7 days were included as 74 
guidelines recommend consideration of therapy switch if persistently bacteremic for almost a 75 
week or sooner if patients condition is worsening despite source control measures.6 Patients on 76 
dialysis during the current admission or previous year and patients with a staphylococcal BSI in 77 
the 30 days prior to admission were excluded.  78 
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 79 
 80 
Data Sources 81 
Clinical data was obtained from the national VA electronic health data which includes 82 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), 83 
diagnostic and procedure codes, chemistry and microbiology data, vitals, and pharmacy data, 84 
including bar code medication administration records.14 This study was approved by the 85 
Institutional Review Board and Research and Development Committee of the Providence 86 
Veterans Affairs Medical Center. 87 
 88 
Variable Definitions 89 
Daptomycin mg/kg dose was calculated based on actual body weight and initial daptomycin 90 
dose, and rounded to the nearest integer. Patients were excluded if they received an initial 91 
daptomycin dose of <5.5 mg/kg, as this is below labeled dose. Patients were then categorized 92 
as daptomycin label dose (6 mg/kg) and higher than label dose (≥7mg/kg). All doses higher than 93 
label dose were included as optimal off-label dose remains undefined and has often include any 94 
dose higher than label dose.13, 15-18 95 
 96 
ICD-9-CM codes were utilized to identify historical and current admission comorbidities. Severity 97 
of illness was assessed using a modified Acute Physiology and Chronic Health Evaluation 98 
(APACHE) III score as previously described within the VA system.19, 20 Age and APACHE III 99 
score were both dichotomized on their medians. Time to initial daptomycin dose and infectious 100 
diseases consult were evaluated from index blood culture. 101 
 102 
The primary outcome assessed was 30-day mortality from index culture. Secondary outcomes 103 
included time to inpatient mortality, hospital discharge, intensive care discharge, creatine 104 
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phosphokinase (CPK) elevations, as well as 30-day readmission and S. aureus reinfection. 105 
Inpatient mortality, hospital discharge, intensive care discharge were measured from index 106 
culture, and 30-day readmission and S. aureus reinfection were assessed from the discharge 107 
date. Baseline creatine phosphokinase (CPK) levels were evaluated for the lowest value during 108 
the 7 days before index blood culture through the 2 days after blood culture. An elevated 109 
baseline CPK was defined as greater than the upper limit of normal (ULN). Elevated CPK levels 110 
from baseline were defined as ≥3 times the ULN if normal baseline CPK and ≥5 times the ULN if 111 
elevated baseline CPK.21 CPK elevations were evaluated for 6 weeks past baseline.  112 
 113 
Statistical analysis 114 
Group differences were evaluated using chi-square or Fisher’s exact tests for categorical 115 
variables and t-test or Wilcoxon rank sum for continuous variables. Propensity scores were 116 
developed based on variables including age, severity of illness, ICU admission, comorbid 117 
conditions, medical history, presence of infectious diseases consult, year of treatment, hospital-118 
onset infection, time to initial daptomycin dose, and source of infection (Supplemental Table 119 
S1). This logistic model was developed using unconditional logistic regression, with backwards, 120 
step-wise elimination.22, 23 Assessments were made for multicollinearity and goodness of fit.24 121 
Caliper matching was performed using a caliper of 0.005, and replacements were not 122 
performed.24 Cox proportional hazard models were used to calculate hazard ratios (HR) and 123 
95% confidence intervals (CI) for the outcomes. Sensitivity analyses were performed with 124 
propensity score quintile adjusted Cox models. 125 
 126 
To determine an optimal daptomycin dose associated with survival, disease risk scores (DRS) 127 
were used to control for confounding variables and subsequently analyzed via a classification 128 
and regression tree (CART) analysis.25, 26 The DRS model was based on all-cause 30-day 129 
mortality and developed among “unexposed” patients (6mg/kg) with the model then being 130 
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applied to higher dose patients to determine their predicted probabilities of the outcome 131 
(Supplemental Table S1). The initial CART analysis included DRS and mg/kg dose. In 132 
sensitivity analyses, weight and creatinine clearance (CrCl) were included in the CART, with 133 
dose being included as mg dose. Mg dose was evaluated as limited PK/PD data suggest “fixed” 134 
mg dose as a possible alternative to mg/kg dose.27 The DRS was also developed using 135 
unconditional logistic regression with backwards, step-wise elimination. CART optimal tree 136 
selection was evaluated using cross-validation to determine pruning by complexity parameter 137 
with the least misclassification error. CART analysis was performed using the rpart package in 138 
R version 3.3.3 (R Foundation for Statistical Computing) while all other analyses were 139 
performed in SAS version 9.2 (SAS Institute, Cary, NC). 140 
 141 
Results 142 
We identified 371 patients with MRSA bacteremia meeting our inclusion and exclusion criteria 143 
(Figure 1) with 138 patients (37.2%) receiving higher than label daptomycin dose (Table 1). 144 
Among patients with higher daptomycin dose (≥7 mg/kg), there were 42.8% (n=59), 50.0% 145 
(n=69), and 7.2% (n=10) patients on 7 mg/kg, 8-9 mg/kg, and ≥10 mg/kg regimens, 146 
respectively. In the overall cohort, patient baseline characteristics and clinical presentation were 147 
similar between dose groups (Table 1). Average body mass index was higher among those 148 
receiving the label dose compared with those treated at higher doses (28.8 vs 27.0; p=0.02). 149 
Likewise, more patients with label dose were obese compared with higher dose (39.9% vs 150 
29.0%; P=0.03). Finally, treatment with label dose vs higher dose varied by treatment period 151 
(2009-2015 74.3% vs 87.7%; P=0.002).  152 
 153 
Propensity score matched 30-day mortality was 18.6% (13/70) in the label dose group and 8.6% 154 
(6/70) in the higher dose group (hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.10-0.94; 155 
Figure 2). No differences were observed in propensity score matched time to inpatient mortality 156 
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(HR 0.13, 95% CI 0.02-1.00), length of stay (HR 1.37, 95% CI 0.83-2.25), 30-day readmission 157 
(HR 0.62, 95% CI 0.31-1.24), or 30-day S. aureus reinfection (HR 1.00, 95% CI 0.25-4.00). In 158 
sensitivity analyses with propensity score quintile adjusted Cox models, none of the outcomes 159 
differed significantly between the label dose and high dose groups. 160 
 161 
Evaluations for an optimal daptomycin dose determined by CART analysis are shown in Figure 162 
3. The DRS partitioned at a predicted probability of 0.51 for 30-day mortality. Further CART 163 
partitioning established a daptomycin dose breakpoint at ≥7mg/kg yielding a 30-day mortality 164 
benefit (P<0.001) among patients with higher DRS (≥51.0%). A significant daptomycin dose 165 
breakpoint was not found among patients with lower DRS (<51.0%).  Consistent with this 166 
absence of partitioning, dose stratification in the low DRS group by 6mg/kg versus ≥7mg/kg 167 
reflected no difference in 30-day mortality (6.1% vs 9.2%; P=0.31). Sensitivity analyses using 168 
mg/kg doses rounded to 0.1 mg had similar results, indicating higher survival with daptomycin 169 
dose at ≥6.6 mg/kg among DRS ≥51.0%. Additional sensitivity analyses adding weight and CrCl 170 
by mg dose did not partition on weight, CrCl, or mg dose. 171 
 172 
In an unmatched safety evaluation of the overall cohort, 73% (273) of patients had CPK levels 173 
and 31.3% (116) had a baseline level. Among patients with a baseline CPK level, a total of 5.2% 174 
had elevations. When stratified by daptomycin dose, CPK elevations were observed in 7.0% 175 
(5/71) of 6 mg/kg, 0% (0/22) of 7 mg/kg, 7.1% (1/14) of 8-9 mg/kg, and 0% (0/3) of ≥10 mg/kg 176 
daptomycin dose regimens. Crude CPK elevations among label vs higher daptomycin dose 177 
were not significantly different (7.0% vs 3.0%; P=0.66). 178 
 179 
Discussion 180 
Our study sought to evaluate clinical outcomes (30-day mortality, inpatient mortality, length of 181 
stay, 30-day readmission, 30-day S. aureus reinfection, and CPK elevations) among those with 182 
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higher than label daptomycin dose (≥7mg/kg vs label dose of 6mg/kg) in MRSA BSI and identify 183 
an optimal daptomycin dose regimen. Consistent with in vitro studies suggesting increased 184 
effectiveness with higher doses9-11, our comparative effectiveness study demonstrated higher 185 
doses were associated with improved survival. These results support current guidelines in 186 
recommending higher than label daptomycin dose in patients with MRSA BSI.5-8 187 
 188 
While two recent studies have concluded higher than labeled daptomycin dose (≥9 and ≥10 189 
mg/kg) translates to improved clinical outcomes in vancomycin-resistant enterococcal (VRE) 190 
BSIs28, 29, our study is the first to establish this evidence in MRSA BSIs. A few studies have 191 
evaluated higher daptomycin dose, however their results have been limited in interpretation for 192 
MRSA BSIs since they included any infection site by any gram-positive organism and most of 193 
these studies lacked a comparison group.13, 16, 30, 31 Studies focusing specifically on BSI with or 194 
without infective endocarditis have also been limited in interpretation due to lack of dose 195 
comparisons and inclusion of all gram-positive organisms.17, 18, 32 196 
 197 
Several in vitro and in vivo studies have suggested advantages of higher daptomycin dose with 198 
increased log reduction of bacterial burden12, 33, more rapid bactericidal activity9, 11, 34-36, and 199 
suppression of non-susceptible isolates.10, 33 Several studies have demonstrated increased 200 
activity with higher daptomycin doses using daptomycin non-susceptible MRSA, hVISA, and 201 
VISA isolates33, 34, though daptomycin non-susceptible isolates are likely rare as a trend 202 
analysis of 12,181 MRSA isolates from medical centers in the United States only found 0.11% 203 
that were daptomycin non-susceptible.37  204 
 205 
Prior to the present study, the most relevant work in determining the impact of higher 206 
daptomycin dose on clinical outcomes in MRSA BSI has been from simulation modeling 207 
performed using data from a randomized, non-inferiority study comparing daptomycin to the 208 
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standard of care for right-sided infective endocarditis.2, 38 In the multivariable analysis of the 209 
simulation study, 24 h AUC/MIC, creatinine clearance, albumin, and disease category (left-sided 210 
endocarditis, right-sided endocarditis or complicated bacteremia, or uncomplicated bacteremia) 211 
were found to be predictors of clinical response.38 Using these data, Monte Carlo simulations 212 
suggested improved clinical success (clinical cure or partial improvement in clinical signs and 213 
symptoms not requiring further treatment) with increased daptomycin exposure among certain 214 
patient populations stratified by outcome probability of response.38 We observed survival 215 
benefits with increased daptomycin exposure which builds on the results of the simulation study, 216 
as our CART analysis identified clinical benefit with higher than label daptomycin dose regimens 217 
among patients with worse survival probabilities. 218 
 219 
Two studies have suggested fixed daptomycin dose may be an alternative to a mg/kg dose.27, 39 220 
One study evaluated fixed dose and clinical outcomes among 50 critically ill patients receiving 221 
6-8 mg/kg/day of daptomycin for Staphylococcus species-related infections. Using those data, 222 
Monte Carlo simulations (MCS) were performed to determine the cumulative fraction of 223 
response (CFR) and risk for muscle toxicity achieved by various fixed dose regimens. Fixed 224 
dose regimens (500 mg and 750 mg for non-septic and septic patients, respectively) achieved 225 
higher CFR than mg/kg dose strategies while simultaneously decreasing probabilities of muscle 226 
toxicities. In our sensitivity analyses, fixed dose was not found to be predictive of 30-day 227 
mortality. Moreover, the small, fixed dose study calculated probabilities of daptomycin trough 228 
levels associated with risk for muscle toxicity to be 4.88-11.0% among non-septic patients. In 229 
contrast, using our more direct surrogate measure of muscle toxicity, CPK, we found elevations 230 
to be infrequent in our cohort, and lower in higher dose group than in the label dose group. Our 231 
results of infrequent CPK elevations are consistent with a recent larger cohort of 911 patients 232 
among whom CPK elevations were rare (<1%) among those receiving higher than label 233 
daptomycin dose.28  234 
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 235 
Several considerations should be made when interpreting our results. As a retrospective 236 
observational study, unmeasured residual confounding may be present. Although all patients 237 
were initiated on vancomycin, vancomycin minimum inhibitory concentrations (MICs) were not 238 
analyzed, however the effect of these on outcomes remains unclear.40 Similarly, daptomycin 239 
MIC was not analyzed, yet MRSA isolates with daptomycin non-susceptibility remains rare.37 240 
We did not evaluate the impact of concomitant or prior MRSA active agents that some patients 241 
may have received. Some data has suggested combination therapy with daptomycin and 242 
another antibiotic may increase effectiveness for MRSA.41, 42 Future studies should consider the 243 
impact of these factors on clinical outcomes. Identification of source control was not available 244 
from our data. Our safety evaluation for CPK elevation was among a limited sample due to lack 245 
of baseline testing for many patients. However, two recent studies evaluating higher daptomycin 246 
dose regimens in VRE have suggested similar rates of elevations compared to label dose.28, 29 247 
Finally, while our CART analysis suggests a benefit with doses of ≥7mg/kg among patients with 248 
higher (>51%) predicted probabilities of 30-day mortality, CART analyses may be sensitive in 249 
determining cutoffs based on the number of observations occurring at a splitting node (N=54 for 250 
the high risk patients).43 As a larger node of patients could have resulted in an alternative cutoff, 251 
we recommend, and believe our data supports, the use of guideline recommended dosing of 8-252 
10 mg/kg for MRSA bacteremia with or without infective endocarditis.6  253 
 254 
Conclusion 255 
This is the first comparative effectiveness study of daptomycin doses in MRSA bacteremia. 256 
Treatment of MRSA bacteremia with higher than label daptomycin doses was associated with 257 
lower rates of 30-day mortality. These data suggest higher doses of daptomycin may be 258 
preferred over label dose to improve survival in MRSA bacteremia, particularly among patients 259 
at high risk of poor outcomes. 260 
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Table 1. Characteristics of patients receiving daptomycin label dose and higher dose 
Characteristic 
Daptomycin Dose 
Overall Cohort 
 
Propensity Matched 
 
6 mg/kg 
(n=233) 
 
≥7 mg/kg 
(n=138) 
P-value 
 
6 mg/kg 
(n=70) 
 
≥7 mg/kg 
(n=70) 
P-value 
Age (years) 64.0 ± 12.7 64.8 ± 9.8 0.55 66.1±9.3 64.5±12.9 0.40 
Male gender 230 (98.7) 132 (95.7) 0.06 69 (98.6) 69 (98.6) 1.00 
Body mass index  28.8 ± 7.0 27.0 ± 6.5 0.02 29.6±7.3 30.6±8.3 0.45 
Obese 93 (39.9) 40 (29.0) 0.03 31 (44.3) 33 (47.1) 0.73 
Year       
2002-2009 60 (25.8) 17 (12.3) 
0.002 
18 (25.7) 16 (22.9) 
0.69 
2010-2015 173 (74.3) 121 (87.7) 52 (74.3) 54 (77.1) 
Charlson score 1.8 ± 1.8 1.9 ± 1.7 0.62 2.1±1.9 2.1±1.9 0.86 
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Commorbidities       
Alcoholism 23 (9.9) 13 (9.4) 0.89 6 (8.6) 5 (7.1) 0.75 
      Diabetes 136 (58.4) 74 (53.6) 0.37 44 (62.9) 45 (64.3) 0.86 
Chronic kidney disease 67 (28.8) 34 (24.6) 0.39 16 (22.9) 24 (34.3) 0.13 
Liver Disease 34 (14.6) 19 (13.7) 0.83 10 (14.3) 13 (18.6) 0.49 
Malignancy 58 (25.0) 37 (26.8) 0.68 14 (20.0) 18 (25.7) 0.42 
Community-onset infectiona 173 (74.3) 106 (76.8) 0.58 51 (72.9) 55 (78.6) 0.43 
Intensive care 47 (20.2) 18 (13.0) 0.08 8 (11.4) 9 (12.9) 0.80 
Severity of illnessb 45.0 ± 18.1 45.4±18.0 0.84 44.8±17.1 44.2±17.8 0.83 
Sources of infectionc       
Endocarditisd 14 (6.0) 11 (8.0) 0.46 7 (10.0) 3 (4.3) 0.19 
Skin and soft tissue culture site 32 (13.7) 13 (9.4) 0.22 8 (11.4) 8 (11.4)  1.00 
Urine 22 (9.4) 13 (9.4) 0.99 9 (12.9) 8 (11.4) 0.80 
Other or unknown 165 (70.9) 101 (73.2) 0.62 46 (65.7) 51 (72.9) 0.36 
Infectious disease consult 172 (73.8) 112 (81.2) 0.11 54 (77.1) 55 (78.6)  0.84 
     Time to consult (days) 3.2±4.1 3.6±4.8 0.38 3.4±4.1 2.8±2.4 0.32 
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Time of vancomycin to daptomycin 
switch (days) 
3.9±1.8  4.0±1.7 0.62 4.0±1.9 4.0±1.7 0.78 
Inpatient daptomycin therapy 
duration (days) 
13.8±17.5 12.4±12.0 0.40 16.3±19.7 13.7±15.7 0.38 
Data are no. (%) and means ± standard deviations; Data are from overall cohort before matching. 
aWithin 72 h of index culture; bModified APACHE III score; cCulture-confirmed source of infection;  dSource of  
infection defined by ICD-9-CM code; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus 
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Figure 1. Flow diagram for inclusion and exclusion 
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Figure 2. Survival probability among patients receiving daptomycin label dose and higher dose 
Legend: Propensity score model C-statistic 0.828, Hosmer and Lemeshow Goodness of Fit p=0.1525, Probability 
distributions by exposure (Supplemental Figure S1). 
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Figure 3. Comparison of 30-day all-cause mortality by classification and regression tree (CART)-derived breakpoints on 
disease risk score (DRS) and daptomycin mg/kg dose 
Legend: Disease risk score model C-statistic 0.959, Hosmer and Lemeshow Goodness of Fit p=0.9493 
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Supplemental Tables 
Table S1: Variables included in final model 
Propensity model Disease risk score model 
• Year, ≥65, ICU admission, sex, hospital (center effects), 
APACHE III, community onset, hepatic failure, ID consult 
• Current diagnosis 
• Diabetes without complications, fluid or electrolyte 
disorder, abscess, administrative/social admission, 
anxiety, diverticulosis/diverticulitis, adverse care, 
gram negative infection, MRSA, nutritional disease, 
peritonitis, lymphoma, valve disease 
• Historical diagnosis (within 1 year) 
• Arrhythmia, renal disease, depression, drug abuse, 
gangrene, abscess, bacterial infection, cataracts, 
cognitive disorder, industrial accident, ear or other 
sensory organ disorder, fever, GI disorder, headache, 
medical, occlusion, osteoarthritis, peritonitis, 
phlebitis, respiratory failure, retinal, septicemia, 
sprain/strain, surgical site infection, streptococcus 
infection, osteoporosis, peptic ulcer disease 
• Source 
• Skin (culture) 
 
• Year, ≥65, ICU admission, hospital (center effects), severe 
sepsis, ID consult, albumin level, operation during current 
admission 
• Current diagnosis 
• Respiratory failure, residual 
• Historical 
• Depression, bacterial infection, lower respiratory, 
osteoporosis 
• Source 
• Endocarditis (ICD-9) 
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Figure S1: Probability distributions by exposure 
 
Note. Dosing group “0” for 6 mg/kg, “1” for ≥7mg/kg 
 
Histograms of Propensity Scores by Dosing Group
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